Gazyva (obinutuzumab)

22:45 EST 23rd November 2017 | BioPortfolio

GAZYVATM (obinutuzumab), in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).

Created at Glycart Biotechnology, Gazyva (obinutuzumab), a type II bioengineered anti-CD20 humanized IgG1 monoclonal, has been developed by Biogen Idec and Roche subsidiaries Genentech and Chugai Pharmaceutical. As with Rituxan® (rituximab), Zevalin® (ibritumomab tiuxetan) and Bexxar® (tositumomab), Gazyva binds to CD20, an activated-glycosylated phosphoprotein target expressed on the surface of all B-cells, causing cell death by apoptosis. It is indicated for use, in combination with chlorambucil, for the treatment of previously untreated CLL.

For full details open - 

Adapted from - Thomson Reuters Cortellis Competitive Intelligence

Quick Search

review and buy Gazyva (obinutuzumab) market research data and corporate reports here